The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 05, 2021

Filed:

Apr. 18, 2017
Applicant:

Faron Pharmaceuticals Oy, Turku, FI;

Inventors:

Maija-Leena Hollmén, Piispanristi, FI;

Miro Viitala, Turku, FI;

Markku Jalkanen, Piispanristi, FI;

Mikael Maksimow, Turku, FI;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
G01N 33/68 (2006.01); C07K 16/28 (2006.01); G01N 33/50 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
G01N 33/6863 (2013.01); C07K 16/28 (2013.01); G01N 33/50 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); G01N 2333/525 (2013.01); G01N 2333/70539 (2013.01); G01N 2333/7151 (2013.01); G01N 2800/52 (2013.01);
Abstract

An agent capable of binding to CLEVER-1 in an individual can be used in activating macrophages to switch their phenotype from M2 macrophages into M1 macrophages. The invention relates to methods for utilizing the macrophages ability to switch their phenotype. In one aspect, the invention relates to a method for estimating of the efficacy of anti-CLEVER-1 therapy by monitoring a modulation of M2 macrophages into M1 macrophages, when an agent capable of binding to CLEVER-1 is administered in a patient, wherein an increased TNF-alpha secretion or HLA-DR expression is indicative of modulation of M2 macrophages into M1 macrophages.


Find Patent Forward Citations

Loading…